Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2023-04-21 00:00:00 ET · period of report 2023-04-19 · accession 0001209191-23-025277 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-21 | 2023-04-19 | VKTX | Lian Brian | Pres, CEO, Dir | S - Sale | $21.45 | -35.0K | 2.24M | -2% | -$750.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2023-04-19 | S | D | 35,000 | $21.45 | 2,242,963 | D | — | — |